138,115 Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 138,115 shares of the company's stock, valued at approximately $909,000. Privium Fund Management B.V. owned 0.42% of Lexeo Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in LXEO. Bank of New York Mellon Corp lifted its position in shares of Lexeo Therapeutics by 5.6% during the 4th quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock valued at $333,000 after acquiring an additional 2,677 shares during the period. BNP Paribas Financial Markets raised its holdings in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares during the last quarter. Rhumbline Advisers boosted its position in Lexeo Therapeutics by 19.6% during the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock worth $166,000 after purchasing an additional 4,127 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock worth $93,000 after purchasing an additional 5,915 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Lexeo Therapeutics in the 4th quarter valued at approximately $46,000. Hedge funds and other institutional investors own 60.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reissued an "outperform" rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics has a consensus rating of "Buy" and a consensus price target of $23.80.

Lexeo Therapeutics Trading Up 0.7 %

Shares of LXEO traded up $0.02 on Friday, hitting $2.71. 513,959 shares of the stock traded hands, compared to its average volume of 302,087. Lexeo Therapeutics, Inc. has a 1 year low of $2.32 and a 1 year high of $19.50. The stock's 50 day moving average is $4.19 and its two-hundred day moving average is $6.79. The firm has a market capitalization of $89.61 million, a P/E ratio of -0.86 and a beta of 3.85. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.